Welcome to our dedicated page for Alterity Therapeutics news (Ticker: ATHE), a resource for investors and traders seeking the latest updates and insights on Alterity Therapeutics stock.
News and updates for Alterity Therapeutics Limited (ATHE) center on its progress as a clinical stage biotechnology company developing disease modifying treatments for neurodegenerative diseases. The company’s announcements emphasize its initial focus on Parkinson’s disease and related disorders, particularly Multiple System Atrophy (MSA), and the development of its lead oral agent ATH434.
Investors and followers of ATHE can expect regular news about clinical trial milestones and data presentations. Alterity has reported positive results from its ATH434‑201 randomized, double‑blind, placebo‑controlled Phase 2 trial in MSA, as well as topline data from the ATH434‑202 open‑label Phase 2 trial in more advanced MSA. Company news often highlights analyses of UMSARS Part I activities of daily living scores, orthostatic hypotension symptom assessments, wearable sensor data, and neuroimaging and biomarker endpoints such as brain iron and the MSA Atrophy Index.
Alterity’s news flow also includes regulatory and designation updates, such as Fast Track Designation by the U.S. Food and Drug Administration and Orphan Drug Designation by the FDA and European Commission for ATH434 in MSA. Additional items cover participation in major neurology and movement disorder conferences, where the company presents new analyses, biomarker findings, and natural history study results, as well as appearances at healthcare and biotech investor events.
On this page, readers can follow announcements about capital raises, quarterly cash flow reports, and corporate presentations that describe Alterity’s cash position, development plans, and engagement with regulators. For those tracking ATHE, the news stream provides context on how the company is advancing ATH434 in MSA, refining its biomarker strategy, and interacting with the scientific and investment communities over time.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) will host an investor webcast to discuss new data from the bioMUSE Natural History Study and its implications for the ATH434-202 Phase 2 trial endpoints. The webcast, set for May 29, 2024, in the U.S. and May 30, 2024, in Australia, will feature CEO Dr. David Stamler and Professor Daniel Claassen from Vanderbilt University. Dr. Claassen, a key opinion leader and principal investigator, will provide insights into the study results and their impact. Registration is required to attend the webcast, where investors can ask questions.
Alterity Therapeutics, a biotechnology company, received positive feedback from the Data Monitoring Committee regarding the Phase 2 clinical trial of ATH434 for the treatment of multiple system atrophy (MSA). The trial is progressing as planned, with top-line data expected in January 2025. The study aims to demonstrate the drug's efficacy, safety, and target engagement through various assessments.
Alterity Therapeutics released its Q3 FY24 Quarterly Cash Flow Report, showcasing promising Phase 2 baseline data for ATH434-201 targeting biomarkers for slowing disease progression. The company raised A$5.25M, received a A$3.9M tax incentive refund, and ended the quarter with A$18.3M in cash. Operational updates include positive DMC review for ATH434-201, presentations at AAN, enrollment progress for ATH434-202, and promising results for ATH434 in Parkinson's disease. The bioMUSE study continues to provide valuable data on MSA progression.
Alterity Therapeutics presented new data at the World Orphan Drug Congress USA 2024 demonstrating the potential of ATH434 to treat Friedreich's Ataxia. The study showed that ATH434 acts as an iron chaperone, redistributing iron in the body, which could help reduce labile iron levels and slow disease progression. The unique iron-binding properties of ATH434 set it apart from traditional iron chelators, making it a promising treatment for neurodegenerative diseases.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Alterity Therapeutics (ATHE)?
What is the market cap of Alterity Therapeutics (ATHE)?
